Grape King Bio Ltd (1707) Fair Value & Analysis

Healthcare · TW · Market cap 13.4B TWD

A solid business, screening 65% undervalued on our models.

What matters now

• The price is below even our cautious bear case (110.10 TWD). The market is more pessimistic than our downside scenario.
• Solid quality (58/100) at a price below fair value, the discount is the argument here, not the business quality.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 23, 2026.

How to read this chart

60‑month range 88.40 TWD – 185.50 TWD · fair‑value band 110.10 TWD – 183.50 TWD · the 89.20 TWD price screens below the 146.80 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 23, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Grape King Bio Ltd (1707) currently trades at 89.20 TWD, while our model-based Fair Value estimate is 146.80 TWD, implying the stock looks roughly 64.6% undervalued today. The Quality Score stands at 58/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.

Over the trailing twelve months, Grape King Bio Ltd generated revenue of 10.3B TWD at a net margin of 11.5%. Revenue grew 1.1% year over year. It earns a return on equity of 15.6%. The balance sheet holds a net cash position of 3.9B TWD. Fundamentals as of Jul 23, 2026

Our scenario range runs from 110.10 TWD (bear case) to 183.50 TWD (bull case); at 89.20 TWD, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 35% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 65%, 1707 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: DCF Models (218.55 TWD) versus Asset-Based (46.77 TWD). Highest evidence: Growth DCF (80).

Key figures & financial health

Quality Score breakdown

About the company

Grape King Bio Ltd, together with its subsidiaries, produces and sells pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy food in Taiwan, China, and internationally. It operates through Multi-Level Marketing; Distributors; Original Design Manufacturer/Original Equipment Manufacturer; and Sales Channel segments.

Full company description

Grape King Bio Ltd, together with its subsidiaries, produces and sells pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy food in Taiwan, China, and internationally. It operates through Multi-Level Marketing; Distributors; Original Design Manufacturer/Original Equipment Manufacturer; and Sales Channel segments. The company provides health products and supplements; and microbial fermentation for mushroom mycelium, probiotics, and enzymes. It also offers functional ingredients for intestinal care, immunity regulation, liver care, brain health, eye care, weight control, feminine health, sensual health care, and others. It serves pharmaceutical preparations, finished drugs, oral liquids, and beverages and health foods. The company was founded in 1969 and is headquartered in Taoyuan City, Taiwan.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Grape King Bio Ltd reported revenue of 10.3B TWD in FY2025 versus 9.8B TWD in FY2021, a compound +1.1%/yr. Reported net income was 1.2B TWD in FY2025, compounding −11.1%/yr from FY2021.

Watch 1707: get an alert when its fair value changes →

Peer Group

Drug Manufacturers - Specialty & Generic · 626 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 23, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.